Unmatched Logistics Solutions for the Life Sciences Industry

Bringing Our Extensive Experience and Compliance Expertise to Your Global Supply Chain

425
Clinical Trials
3
Commercial Products
270,000+
Shipments
100+
Countries
q3-notification 

Upcoming Events View All

NOV11

BIO-Europe

Date: November 11 - 13, 2019
Location:Hamburg, Germany

DEC4

Cell Therapy Manufacturing & Gene Therapy Congress

Date: December 4 - 6, 2019
Location: Amsterdam, The Netherlands

The Latest From Our Blog View All

VIDEO: Complying with Critical Regulations: Cryoport’s Chain of Compliance ™

Precision medicine requires end-to-end traceability: everything from chain of custody, to chain of condition, to chain of identity. But the fragility of regenerative medicine therapies – and the need to more effectively manage risk– means that a fourth chain will soon be a regulatory requirement: the Chain of Compliance™. Enhanced traceability within the temperature-controlled and cold chain logistics distribution will soon be subjected to additional regulatory requirements due to the fragile aspect of the drug product and the disproportionate risk of improper cold chain management on the viability of the therapies. 

As Cell Therapy Approvals Speed Up, Companies Struggle with Manufacturing Demands

Early approvals of upcoming cell therapies have moved up manufacturing timelines for many firms in the biotech space. This blaze of approvals has been ignited by positive early clinical trial data, and now manufacturers are facing the substantial logistical challenges of scaling their products into the commercial stage.